Article
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2024
Jain Nitin, Croner Lisa J, Allan John N, Siddiqi Tanya, Tedeschi Alessandra, Badoux Xavier C, Eckert Karl, Cheung Leo W K, Mukherjee Anwesha, Dean James P, Szafer-Glusman Edith, Seymour John F
Abstract excerpt
PURPOSE: Mutations in BTK, PLCG2, and BCL2 have been reported in patients with progressive disease (PD) on continuous single-agent BTK or BCL2 inhibitor treatment. We tested for these mutations in samples from patients with PD after completion of first-line treatment with fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL) in the phase II CAPTIVATE study. PATIENTS AND METHODS: A total...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.